Mednax Inc. (NYSE:MD)‘s stock had its “buy” rating restated by equities research analysts at Mizuho in a report released on Tuesday. They currently have a $79.00 price objective on the stock. Mizuho’s target price suggests a potential upside of 21.00% from the stock’s previous close.
Several other equities analysts have also recently weighed in on MD. Jefferies Group reissued a “buy” rating and issued a $80.00 target price on shares of Mednax in a research note on Wednesday, June 8th. Zacks Investment Research raised shares of Mednax from a “hold” rating to a “buy” rating and set a $80.00 target price for the company in a research note on Wednesday, June 29th. JPMorgan Chase & Co. decreased their target price on shares of Mednax from $85.00 to $80.00 and set an “overweight” rating for the company in a research note on Friday, July 29th. Finally, Citigroup Inc. decreased their target price on shares of Mednax from $76.00 to $72.00 and set a “neutral” rating for the company in a research note on Wednesday, August 17th. Four equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. Mednax presently has a consensus rating of “Buy” and an average price target of $76.11.
Shares of Mednax (NYSE:MD) opened at 65.29 on Tuesday. Mednax has a one year low of $61.40 and a one year high of $84.37. The firm has a 50-day moving average of $65.52 and a 200 day moving average of $68.17. The company has a market cap of $6.02 billion, a price-to-earnings ratio of 18.22 and a beta of 0.56.
Mednax (NYSE:MD) last released its earnings results on Thursday, July 28th. The company reported $1.03 earnings per share for the quarter, missing the consensus estimate of $1.07 by $0.04. Mednax had a net margin of 11.17% and a return on equity of 14.88%. The firm earned $772 million during the quarter, compared to the consensus estimate of $775.68 million. During the same period in the prior year, the business posted $0.90 earnings per share. Mednax’s quarterly revenue was up 14.1% compared to the same quarter last year. Equities research analysts anticipate that Mednax will post $4.14 EPS for the current year.
In other news, Director Md Pascal J. Goldschmidt sold 1,500 shares of Mednax stock in a transaction on Wednesday, September 14th. The stock was sold at an average price of $65.01, for a total transaction of $97,515.00. Following the completion of the sale, the director now owns 12,755 shares of the company’s stock, valued at $829,202.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 2.40% of the company’s stock.
Several large investors have recently bought and sold shares of MD. Norges Bank purchased a new stake in Mednax during the fourth quarter worth $59,563,000. Fjarde AP Fonden Fourth Swedish National Pension Fund increased its stake in Mednax by 11.7% in the first quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 28,741 shares of the company’s stock worth $1,857,000 after buying an additional 3,010 shares in the last quarter. GW&K Investment Management LLC increased its stake in Mednax by 8.2% in the first quarter. GW&K Investment Management LLC now owns 319,889 shares of the company’s stock worth $20,671,000 after buying an additional 24,217 shares in the last quarter. Sarasin & Partners LLP increased its stake in Mednax by 22.2% in the first quarter. Sarasin & Partners LLP now owns 17,600 shares of the company’s stock worth $1,137,000 after buying an additional 3,200 shares in the last quarter. Finally, Aperio Group LLC increased its stake in Mednax by 19.8% in the first quarter. Aperio Group LLC now owns 18,972 shares of the company’s stock worth $1,226,000 after buying an additional 3,136 shares in the last quarter. 97.75% of the stock is owned by institutional investors.
MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. The Company’s national network consists of approximately 3,240 affiliated physicians, including approximately 1,100 physicians who provide neonatal clinical care, in over 30 states and Puerto Rico, within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.
Receive News & Ratings for Mednax Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mednax Inc. and related companies with MarketBeat.com's FREE daily email newsletter.